Medicare has announced that it will continue to pay in full for Provenge, an immunotherapy for treating advanced prostate cancer, as long as it is used along with label indications, according to a ...

Dendreon's (NASDAQ:DNDN) prostate cancer vaccine Provenge is under scrutiny again from longtime gadfly Marie Huber. She alleges that the studies by the company leading up to FDA approval for the drug ...

For a few brief months earlier this year, Dendreon‘s Provenge looked like it might become the first cancer vaccine approved by the FDA, despite some iffy data supporting its effectiveness. The fate of ...

NEW YORK, Oct 7 (Reuters) - Interest in Dendreon Corp's Provenge vaccine to treat prostate cancer seems to be waning following recent approval of Johnson & Johnson's more-convenient and faster-acting ...

NEW YORK (Reuters) - Prostate cancer vaccine Provenge has long incited passions unlike any other cancer therapy. Doctors who raised doubts about it received death threats. Health regulators and ...

The safety evaluation of PROVENGE was based on 601 prostate cancer patients in four randomized clinical trials who underwent at least one leukapheresis. The most common adverse events (incidence ...

NEW YORK, March 30 (Reuters) - Prostate cancer vaccine Provenge has long incited passions unlike any other cancer therapy. Doctors who raised doubts about it received death threats. Health regulators ...